Micro Therapeutics CE-marks liquid embolic system:
This article was originally published in Clinica
Executive Summary
Micro Therapeutics has CE-marked its ONYX liquid embolic system for the endovascular treatment of arteriovenous malformations (AVMs) in the brain, abnormal formations of arteries and veins that are prone to rupturing. ONYX, previously called EMBOLYX, acts as a vascular "blocking agent". It is delivered in a liquid form via microcatheters to the intended site where it quickly transforms into a solid polymer mass, filling the targeted vascular malformation. The Irvine, California-based company said that US firm Guidant will market the product in most of Europe.